July 11, 2023
All orders include full batch documentation and are packaged to maintain peptide integrity during transit
The current study Study author Yuya Koide and his colleagues wanted to explore how individuals with type 2 diabetes respond to GLP-1RAs therapy (Koide et al., 2025)
FDA-approved GLP-1 medications like semaglutide (Ozempic, Wegovy) are structurally modified to resist breakdown, have half-lives of days rather than minutes, and produce sustained receptor activation that results in greater glucose-lowering effects and clinically significant weight loss
In a study led by Marathe et al., retatrutide-induced weight loss reduced tumor engraftment, delayed tumor onset, and significantly attenuated tumor growth in pancreatic and lung cancer models, with greater tumor suppression than the GLP-1 receptor agonist semaglutide
Constipation and diarrhea, as well as some abdominal discomfort and bloating, are other G.I